DBV Technologies appoints Philina Lee to Board of Directors effective October 30, 2025

DBV Technologies S.A.

Lee replaces Daniel Soland; appointment subject to shareholder ratification at next annual meeting.
She previously served as Chief Commercial Officer of Blueprint Medicines, leading AYVAKIT launch.
Lee will serve on the Compensation Committee of the Board.
She will receive an annual retainer of €100,000 plus €5,000 for committee service.
Company now has ten board members; Lee brings biopharma commercialization experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.